Drop-out rates of cancer patients participating in longitudinal RCTs

Mathibe, Lehlohonolo J.

doi:10.1016/j.cct.2007.03.006

Cited by 17 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that patients with higher disease stages were more likely to decline trial participation and to dropout over the course of the study. These findings are in line with those of other studies (Colangelo et al., ; Jimenez et al., ; Mathibe, ; Paul et al., ). Similar findings were observed among patients with metastases (Osoba & Zee, ).…”

Section: Discussionsupporting

confidence: 93%

Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial

et al. 2017

View full text Add to dashboard Cite

We investigated the impact of demographic and disease related factors on nonparticipation and dropout in a cluster-randomised behavioural trial in cancer patients with measurements taken between hospitalisation and 6 months thereafter. The percentages of non-participation and dropout were documented at each time point. Factors considered to be potentially related with non-participation and dropout were as follows: age, sex, marital status, education, income, employment status, tumour site and stage of disease. Of

show abstract

Section: Discussionsupporting

confidence: 93%

Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The failure of candidates to acknowledge the protocol design may culminate in a disastrous level of participation. In our institution, after introducing the humanistic approach to clinical research, we observed a lower percentage of dropouts in comparison with other reports, in which attrition rates ranged from 20% to 30% [34]. The humanistic approach to clinical research activities took several years to implement due to the time required to develop training, validate standard procedures, and instil a humanistic culture.…”

Section: Specific Trainingmentioning

confidence: 61%

Bringing a humanistic approach to cancer clinical trials

Arai

Longo

Sponton

et al. 2017

ecancer

View full text Add to dashboard Cite

In this article, we describe some practical aspects that promote the humanisation of clinical research. Actions are not limited to improving the communication skills of medical staff but also include maintenance of care continuity, accessible written information, and application of theoretic models such as shared decision-making and management of stress in decision-making under uncertainty. We believe that a comprehensive strategy will increase patients’ motivation to participate in and adhere to clinical research.

show abstract

“…Sensitivity analyses evaluate potential bias caused by missing values in follow-up measures to ensure peak sensitivity at all time points [52, 53] and reliability at time points where attrition is less than 30%. Sensitivity analyses are typically conducted to assess the effect of dropouts on inferences about the target parameters, and are particularly important when the treatment arms are unequal [53].…”

Section: Methodsmentioning

confidence: 99%

Short-term Hormone Therapy with Transdermal Estradiol Improves Cognition for Postmenopausal Women with Alzheimer's Disease: Results of a Randomized Controlled Trial

Wharton

Baker

Gleason

et al. 2011

JAD

View full text Add to dashboard Cite

We aimed to conduct a placebo-controlled, double-blind, parallel-group design intervention study to evaluate the therapeutic efficacy of hormone therapy (HT) in postmenopausal women with mild to moderate Alzheimer’s disease (AD). The trial was designed to evaluate the dose-dependent effects of transdermal 17-β estradiol, unopposed and opposed with medroxyprogesterone (MPA, Provera©), for 12 months in 43 postmenopausal women with AD. Participants were assessed using cognitive measures at baseline, months 1, 3, 6, and 12 of treatment and eight weeks post treatment (month 15). The dropout rate was 49% across 12 months. As a result of theWomen’s Health Initiative (WHI) and anticipated increased attrition, the protocolwas modified to examine data only at time points where attrition was less than 30%. The results of sensitivity analyses indicated robust and reliable data collected in the first three months of the trial. Data collected in the first three months of the trial for forty-three participants were analyzed. HT had favorable cognitive effects across multiple cognitive domains, including visual memory (p-values < 0.030) and semantic memory (p-values < 0.037) in postmenopausal women with AD. Moreover, treatment-related changes in plasma estradiol were positively correlated with improvements in visual memory. Short-term HT that includes the use of estradiol has favorable effects on cognition in women with AD.

show abstract

Drop-out rates of cancer patients participating in longitudinal RCTs

Cited by 17 publications

References 13 publications

Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial

Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial

Bringing a humanistic approach to cancer clinical trials

Short-term Hormone Therapy with Transdermal Estradiol Improves Cognition for Postmenopausal Women with Alzheimer's Disease: Results of a Randomized Controlled Trial

Contact Info

Product

Resources

About